- Home
- SWIN vs COEP Comparison
SWIN vs COEP Comparison
Compare SWIN & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- COEP
- Stock Information
- Founded
- SWIN 2017
- COEP 2017
- Country
- SWIN Hong Kong
- COEP United States
- Employees
- SWIN N/A
- COEP N/A
- Industry
- SWIN
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SWIN
- COEP Health Care
- Exchange
- SWIN Nasdaq
- COEP Nasdaq
- Market Cap
- SWIN 32.1M
- COEP 32.0M
- IPO Year
- SWIN 2023
- COEP N/A
- Fundamental
- Price
- SWIN $3.06
- COEP $8.03
- Analyst Decision
- SWIN
- COEP
- Analyst Count
- SWIN 0
- COEP 0
- Target Price
- SWIN N/A
- COEP N/A
- AVG Volume (30 Days)
- SWIN 292.8K
- COEP 25.9K
- Earning Date
- SWIN 08-21-2025
- COEP 08-15-2025
- Dividend Yield
- SWIN N/A
- COEP N/A
- EPS Growth
- SWIN N/A
- COEP N/A
- EPS
- SWIN N/A
- COEP N/A
- Revenue
- SWIN $2,419,000.00
- COEP $62,874.00
- Revenue This Year
- SWIN N/A
- COEP N/A
- Revenue Next Year
- SWIN $61.68
- COEP N/A
- P/E Ratio
- SWIN N/A
- COEP N/A
- Revenue Growth
- SWIN N/A
- COEP N/A
- 52 Week Low
- SWIN $1.16
- COEP $2.31
- 52 Week High
- SWIN $4.17
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- SWIN 79.41
- COEP 43.91
- Support Level
- SWIN $1.57
- COEP $6.80
- Resistance Level
- SWIN $3.48
- COEP $8.86
- Average True Range (ATR)
- SWIN 0.26
- COEP 0.62
- MACD
- SWIN 0.13
- COEP -0.05
- Stochastic Oscillator
- SWIN 78.05
- COEP 45.88
About SWIN Solowin Holdings
Solowin Holdings Ltd is a investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secured one-stop electronic platform. It is engaged in providing securities related services, investment advisory service, and asset management service to customers. The operations were organized into four reportable segments: securities related services, investment advisory services, corporate consultancy services, and asset management services. It derives maximum revenue from investment advisory services.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.